Evidence map›Paper›PMID 33613924›Full record

ArticleRare tumors2021

Prolonged survival with systemic chemotherapy in an advanced malignant mesothelioma: A case report.

Mohamed Amine Elghali, Rym Bourigua, Imtinene Belaid, Salsabil Nasri, Sara Mestiri, Sara Yaacoub, Amine Makni, Rached Letaief

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Rare tumors, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Mohamed Amine ElghaliDepartment of Digestive Surgery, University of Sousse, Faculty of Medicine, Farhat Hached University Hospital, Sousse, Tunisia.ORCID https://orcid.org/0000-0001-9971-0747
Rym BouriguaDepartment of Medical Oncology, University of Sousse, Faculty of Medicine, Farhat Hached University Hospital, Sousse, Tunisia.
Imtinene BelaidDepartment of Medical Oncology, University of Sousse, Faculty of Medicine, Farhat Hached University Hospital, Sousse, Tunisia.
Salsabil NasriDepartment of Digestive Surgery, University of Sousse, Faculty of Medicine, Farhat Hached University Hospital, Sousse, Tunisia.ORCID https://orcid.org/0000-0001-9565-3562
Sara MestiriDepartment of Pathology, University of Sousse, Faculty of Medicine, Farhat Hached University Hospital, Sousse, Tunisia.
Sara YaacoubDepartment of Pathology, University of Sousse, Faculty of Medicine, Farhat Hached University Hospital, Sousse, Tunisia.
Amine MakniDepartment of Digestive Surgery, University of Tunis, Faculty of Medicine, La Rabta University Hospital, Tunis, Tunisia.
Rached LetaiefDepartment of Digestive Surgery, University of Sousse, Faculty of Medicine, Farhat Hached University Hospital, Sousse, Tunisia.
Hôpital Farhat Hached · TNHôpital La Rabta · TN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Peritoneal mesotheliomas are very rare tumors. Their prognosis is poor, average survival does not exceed 1 year after peritoneal cytoreduction. Systemic chemotherapy is considered to have no proven value in the management of peritoneal mesotheliomas. Objective responses with systemic chemotherapy are very rare. We report here a case of an advanced peritoneal mesothelioma which achieved an unexpected partial response with chemotherapy, allowing the patient to have a right colectomy. The patient was referred to a specialized center on HIPEC, but taking in account the long awaiting interval, the HIPEC was judged to be inefficient and then the poursuit of 6 cycles of systemic chemotherapy was decided. The patient is still alive without any symptom and with a good performance status at 59 months after diagnosis. Throughout our case, we provide an encouraging evidence of the role of initial systemic chemotherapy in the downstaging of initially unresectable primary malignant mesothelioma and in the improvement of overall survival.

Indexed as

chemotherapyPeritoneal mesotheliomasurgerysurvival

Identifiers

PMID33613924
PMCPMC7874336
OpenAlexW3128761619

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.